Lung Oncologists Take to Social Media to Highlight Impactful WCLC Abstracts

Leveraging #WCLC25, lung oncologists spoke about the presentations they’re most looking forward to at the upcoming conference.

The 2025 IASLC World Conference on Lung Cancer (WCLC) is right around the corner, and CancerNetwork® has put its social listening skills to the test. X (formerly Twitter) has been taken by storm, utilizing #WCLC25, top clinicians are ready to discuss what they’re most excited about.

Take a sneak peek at what the conference has in store. Be sure to tune in to the CancerNetwork® site beginning on September 6th for the full conference coverage.

#1 Phase 3 HARMONi-A in NSCLC

Steven V. Liu, MD, associate professor of medicine at Georgetown University and Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center, highlighted results from the phase 3 HARMONi-A trial (NCT05184712), which recently released the overall survival (OS) data.

The trial assessing ivonescimab in patients with non–small cell lung cancer (NSCLC) met the OS end point and had a statistically significant and clinically meaningful OS benefit.1

On X, Liu stated, “Ivonescimab (PD1/VEGF bispecific) + chemotherapy vs chemo in #EGFR NSCLC post TKI already showed PFS benefit (7.1m vs 4.8m) but OS was in question. Full results to be presented at #WCLC25.”2

#2 FLAURA-2 OS Results

The long-awaited OS results for the phase 3 FLAURA-2 trial (NCT04035486) investigating osimertinib (Tagrisso) with or without chemotherapy as a first-line treatment for patients with EGFR NSCLC will be presented at the conference. Balazs Halmos, MD, professor in the Department of Oncology, professor in the Department of Medicine, and associate director of Clinical Science at Montefiore Albert Einstein Comprehensive Cancer Center, gave a unique look at this announcement.

Halmos, playing off the recent engagement of Taylor Swift and Travis Kelce, noted, “FLAURA-2 OS update at #WCLC25- after years of dating, will #lcsm celebrity osi and strongman chemo finally tie the knot for good?”3

#3 A Hodge-Podge of Exciting Trials

Aakash Desai, MD, MPH, FASCO, created a chart to track and follow the most pressing trials from WCLC. Among them were HARMONi and FLAURA-2, with one of the most intriguing being the phase 1/2 ARROS-1 trial (NCT05118789). The trial, assessed zidesamtinib for patients with advanced NSCLC who have a ROS1 rearrangement.

In the image, Desai wrote, “Exciting to see drugs being developed in the space for pre-treated cohorts.”

Desai is an assistant professor of medicine at the O’Neal Cancer Center, University of Alabama, Birmingham.

#4 Pumitamig Plus Chemotherapy in First-Line Early-Stage SCLC

Next, Hidehito Horinouchi, MD, PhD, highlighted BNT327 (Pumitamig), a PD-L1 and VEGF-A bispecific antibody plus chemotherapy in the first-line setting for patients with early-stage small cell lung cancer.4 The trial, presented by John Heymach, MD, is set to show that pumitamig plus etoposide/carboplatin had acceptable efficacy and safety. This will be the first presentation of this phase 2 trial (NCT06449209), globally.

Horinouchi, assistant chief of the Department of Thoracic Oncology at the National Cancer Center Hospital in Japan, wrote: ☑️#WCLC25 #LCSM Oral🆙 🔥BNT327 (Pumitamig; PD-L1 x VEGF-A bsAb)

🔥Global Phase 2 Randomized Trial of BNT327 (Pumitamig; PD-L1 x VEGF-A bsAb) + Chemotherapy for 1L ES-SCLC: Dose Optimization Analysis

🎙️ Dr. John Heymach

#5 Multidisciplinary Cancer Care

Finally, Eric K. Singhi, MD, will be presenting on survivorship. He will focus on personalized cancer care. In his X post, Singhi noted how he was excited to lean into the multidisciplinary aspect of his practice and be able to speak on a side of care not often considered, especially involving the use of social media.

Singhi is an assistant professor in the Department of General Oncology, Division of Cancer Medicine and assistant professor in the Department of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center.

References

1. Akeso says ivonescimab delivers OS win in lung cancer trial. News release. First World Pharma. August 26, 2025. Accessed September 2, 2025. https://tinyurl.com/ynej46a7
2. @StephenVLiu. Akeso reports Phase III HARMONi-A trial positive for survival. Ivonescimab (PD1/VEGF bispecific) + chemotherapy vs chemo in #EGFR NSCLC post TKI already showed PFS benefit (7.1m vs 4.8m) but OS was in question. Full results to be presented at #WCLC25. August 25, 2025. Accessed September 2, 2025. https://tinyurl.com/2p9tmsfz
3. @BalazsHalmosMD. FLAURA-2 OS update at #WCLC25- after years of dating, will #lcsm celebrity osi and strongman chemo finally tie the knot for good. August 26, 2025. Accessed September 2, 2025. https://tinyurl.com/mth9jkkb
4. @ADesaiMD. 🚨 Plans for the long weekend?🤔 Get ready for #WCLC25!🌍 Amazing science awaits... ➡️Check out my top picks! 💥 What are some others you are excited about? @LungCancerRx @OncBrothers @OncoAlert @IASLC @DrJNaidoo @UmbertoMalapel1 @NReguart @IsaOpitz. August 30, 2025. Accessed September 2, 2025. https://tinyurl.com/3ee4dz97
5. @HHorinouchi. ☑️#WCLC25 #LCSM Oral🆙 🔥BNT327 (Pumitamig; PD-L1 x VEGF-A bsAb) 🔥Global Phase 2 Randomized Trial of BNT327 (Pumitamig; PD-L1 x VEGF-A bsAb) + Chemotherapy for 1L ES-SCLC: Dose Optimization Analysis🎙️ Dr. John Heymach @OncoAlert @Larvol @IASLC https://cattendee.abstractsonline.com/meeting/21151/Session/243. August 15, 2025. Accessed September 2, 2025. https://tinyurl.com/3s4dxvjr
6. @lungoncdoc. If you told me a few years ago I’d be invited to speak at @IASLC #WCLC25, not just on research, but on how social media fuels patient education & advocacy, I’d have said you were CRAZY. Lean into what you love. Even if it’s not the norm. Especially when it helps patients 🤍. August 28, 2025. Accessed September 2, 2025. https://tinyurl.com/5342umuc